Présentation :
Médecin responsable de la salle d'hospitalisation d'hématologie.
Localisation(s) :
Lundi |
Mardi |
Mercredi |
Jeudi |
Vendredi |
Samedi |
Matin |
Après-midi |
Matin |
Après-midi |
Matin |
Après-midi |
Matin |
Après-midi |
Matin |
Après-midi |
Matin |
Après-midi |
|
|
|
|
|
|
|
|
|
|
|
|
Ce tableau est donné à titre indicatif. Il ne tient pas compte des congés ou modifications éventuelles
La Chapelle (Liège-Centre)
- “Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival.”
Jaspers A, Baron F, Servais S, Lejeune M, Willems É, Seidel L, Hafraoui K, Bonnet C, BeguinY.
Am J Hematol. 2015 Sep;90(9):E197-9.
- “Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.”
Jaspers A, Baron F, Maertens J, De Prijck B, Schots R, Bonnet C, Hafraoui K, Willems E,
Servais S, Fillet G, Beguin Y.
Am J Hematol. 2015 Jul;90(7):E133-4.
- “Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas.”
Beguin Y, Jaspers A.
Expert Opin Pharmacother. 2014;15(14):2087-2103.
- “Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomized trial.”
Jaspers A, Baron F, Willems E, Seidel L, Hafraoui K, Vanstraelen G, Bonnet C, Beguin Y.
Blood. 2014;124(1):33-41.
- “Serum hepcidin following autologous hematopoietic cell transplantation: an illustration of the interplay of iron status, erythropoiesis and inflammation.”
Jaspers A, Baron F, Willems E, Seidel L, Wiegerinck ET, Swinkels DW, Beguin Y.
Haematologica. 2014 Mar;99(3):e35-7.
- “Darbepoetin alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial.”
Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E,
Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.
Am J Hematol 2013;88:990‐996.
- “A novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia (IRIDA).”
Jaspers A, Caers J, Le Gac G, Ferec C, Beguin Y, Fillet G.
Br J Haematol. 2013 Feb;160(4):564-5.
- “Le lymphome du manteau.“
Jaspers A, Baron F, Bonnet C, De Prijck B, Fassotte MF, Beguin Y.
Rev Med Liege. 2010 Apr;65(4):171-6.